Skip to main content
TipRanks
Go Ultimate75% OFF

AXA SA (AXAA) AI Stock Analysis

6 Followers
DE:AXAA

AXA SA

(Frankfurt:AXAA)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Broad operating momentumStrong P&C underwriting and accelerating Life & Health results show breadth across AXA’s major businesses. A 90.1% combined ratio, 11% earnings growth and 53% technical-margin increase support resilient earnings and reduce reliance on any single product line.
Negative Factors
Asset-base contractionA declining asset base may indicate reduced business scale or portfolio repositioning that could constrain future premium generation and investment income. Although leverage improved sharply, the multi-year contraction warrants monitoring because it may limit the balance-sheet resources supporting expansion.

AXA SA (AXAA) vs. iShares MSCI Germany ETF (EWG)

-10%-5%0%5%10%15%20%25%30%DE:AXAA+22.30%EWG+6.38%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 107.55B
Dividend Yield
5.07%
Average Volume (3M)
1,258
Price to Earnings (P/E)
9.4
Beta (1Y)
0.64
Revenue Growth
10.86%
EPS Growth
36.10%
Country
Germany
Employees
103,423
Sector
Financial
Sector Strength
68
Industry
Insurance - Diversified

AXA SA Business Overview & Revenue Model

Company Description

AXA SA is a global financial services group, operating through its subsidiaries to deliver insurance, asset management, and banking solutions worldwide. Its operations are segmented across regions like France, Europe, and Asia, alongside specialized...

AXA SA Earnings Call Summary

Earnings Call Date:Jul 31, 2026(Q2-2026)|% Change Since:0.90%|Next Earnings Date:Feb 25, 2027
Earnings Call SentimentPositive

The call highlights broad, high-quality and relatively consistent operational and financial performance: double-digit earnings growth in Life & Health, mid-single-digit P&C earnings growth, strong UEPS growth (+8%), attractive ROE (18%) and a very robust Solvency II ratio (218%). Investment income, disciplined expense reductions and strong new business momentum (2m net new contracts) underpin confidence for FY2026 guidance. Headwinds are largely specific and manageable: a EUR 0.1bn Middle East loss, FX weakness (-3%), seasonal absence of H1 real estate gains (-EUR 0.2bn financial flows), and some localized pricing softness (UK motor, North America property, Mexico). Overall, positives significantly outweigh the challenges, giving a constructive outlook for the remainder of 2026.

Positive Updates

Strong Top-Line and UEPS Growth
Organic top-line growth of +5% and underlying earnings per share (UEPS) up +8%, at the top end of the 6%–8% target range.

Negative Updates

Middle East Losses Impact
AXA XL incurred EUR 0.1bn of losses related to the Middle East in H1, contributing ~30 bps to the P&C combined ratio and including a mix of case reserves (~1/3) and IBNR (~2/3).

Company Guidance

Management reiterated confidence in delivering full‑year 2026 underlying earnings per share (UEPS) growth at the upper end of its 6–8% target range, after reporting H1 results including organic top‑line growth +5%, UEPS +8% (underlying earnings +4% at group level, +9% excl. AXA IM), return on equity 18% and a Solvency II ratio of 218% (215% at Jan 1, H1 movement: +17 pts normalized capital generation, −12 pts dividends/buybacks, −3 pts economic variance). They highlighted strong P&C momentum — earnings +6%, combined ratio 90.1% (↑10bps YoY, +30bps ex‑Prima, Nat Cat 3.5% vs a normalized 4.5%), non‑commission expense 9.7% (40bps improvement) and low PYD reliance (−1pt) — and said investment income is a tailwind supported by reinvestment at ~4.6%. AXA XL earnings grew +4% with pricing contained at about −1% and ~30bps benefit from lower reinsurance; Life & Health premiums +8% and earnings +11% (short‑term revenues +5%, technical margin +53%, combined ratio 96%, long‑term net flows up from €2.2bn to €3.0bn, CSM release +6% with FY26 CSM release guidance >3%). They also confirmed cash remittance ambitions above €21bn for the plan, ~€10bn mid‑market lending exposure (avg ticket €7–8m), Prima pro‑forma combined ratio ~87.5% with ~€2bn reserves and target to recapture ~90% of Prima premiums by 2027 (≈€0.9bn recapture expected in 2026), and continued cost‑efficiency delivery (group non‑commission expense rollback ~30bps in 2026 and −50bps target over the plan).

AXA SA Peers Comparison

Overall Rating

UnderperformOutperform
Sector (68)

Financial Indicators

DE:AXAA against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
HIGHIG82Outperform$36.85B8.2324.13%1.75%4.08%34.70%
ACGLACGL81Outperform$35.53B8.8218.35%―-5.29%14.08%
BRK.BBRK.B78Outperform$1.25T16.4610.43%―6.24%14.58%
AIGAIG77Outperform$42.68B13.418.18%2.29%1.19%9.77%
AEGAEG74Outperform$12.93B12.0712.23%5.60%24.97%―
Sector *68Neutral$18.00B11.429.92%3.81%9.73%1.22%

* Financial Sector Average

Performance Comparison

-10%0%10%20%DE:AXAAAEGAIGACGLHIGBRK.BDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:AXAA and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:AXAAAXA SA44.807.9821.66%
AEGAegon Nv8.671.1315.02%
AIGAmerican International Group, Inc.82.856.388.35%
ACGLArch Capital109.1716.4117.69%
HIGHartford Insurance Group Inc137.185.854.46%
BRK.BBerkshire Hathaway B588.2475.1314.64%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.